SWANBIO THERAPEUTICS Trademark

Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders; none of the foregoing constituting reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays

Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development; none of the foregoing relating to reagents or probes or for the purpose of detecting and analyzing molecules in protein or nucleotide arrays